Perirenal hematoma associated with bevacizumab treatment.

Hidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa

Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

Investigational new drugs 2012 Apr

filter terms:

We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy. CT-scan was consistent with perirenal hematoma and discontinuation of bevacizumab resulted in symptomatic improvement. Nontraumatic perirenal hematoma is a rare condition that can cause shock in severe cases. Given that several types of bleeding complication are known to be associated with bevacizumab treatment, we concluded that bevacizumab likely contributed to the perirenal hematoma in this case. Although the appropriate modification of bevacizumab treatment in the setting of perirenal hematoma is still unclear, physicians should be aware of this potential bevacizumab-associated bleeding complication.

Citation

Hidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa. Perirenal hematoma associated with bevacizumab treatment. Investigational new drugs. 2012 Apr;30(2):808-9